Next Article in Journal
Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension
Previous Article in Journal
Unusual Antioxidant Properties of 26S Proteasome Isolated from Cold-Adapted Organisms
Open AccessArticle

The Pharmaceutical Device Prisma® Skin Promotes in Vitro Angiogenesis through Endothelial to Mesenchymal Transition during Skin Wound Healing

1
Department of Pharmacy, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano (Salerno), Italy
2
Primary Care—Wound Care Service, Health Local Agency Naples 3 South, Via Libertà 42, 80055 Portici (Napoli), Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(8), 1614; https://doi.org/10.3390/ijms18081614
Received: 29 June 2017 / Revised: 12 July 2017 / Accepted: 22 July 2017 / Published: 25 July 2017
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Glycosaminoglycans are polysaccharides of the extracellular matrix supporting skin wound closure. Mesoglycan is a mixture of glycosaminoglycans such as chondroitin-, dermatan-, heparan-sulfate and heparin and is the main component of Prisma® Skin, a pharmaceutical device developed by Mediolanum Farmaceutici S.p.a. Here, we show the in vitro effects of this device in the new vessels formation by endothelial cells, since angiogenesis represents a key moment in wound healing. We found a strong increase of migration and invasion rates of these cells treated with mesoglycan and Prisma® Skin which mediate the activation of the pathway triggered by CD44 receptor. Furthermore, endothelial cells form longer capillary-like structures with a great number of branches, in the presence of the same treatments. Thus, the device, thanks to the mesoglycan, leads the cells to the Endothelial-to-Mesenchymal Transition, suggesting the switch to a fibroblast-like phenotype, as shown by immunofluorescence assays. Finally, we found that mesoglycan and Prisma® Skin inhibit inflammatory reactions such as nitric oxide secretion and NF-κB nuclear translocation in endothelial cells and Tumor Necrosis Factor-α production by macrophages. In conclusion, based on our data, we suggest that Prisma® Skin may be able to accelerate angiogenesis in skin wound healing, and regulate inflammation avoiding chronic, thus pathological, responses. View Full-Text
Keywords: mesoglycan; Prisma® Skin; glycosaminoglycans; angiogenesis; skin wound healing mesoglycan; Prisma® Skin; glycosaminoglycans; angiogenesis; skin wound healing
Show Figures

Graphical abstract

MDPI and ACS Style

Belvedere, R.; Bizzarro, V.; Parente, L.; Petrella, F.; Petrella, A. The Pharmaceutical Device Prisma® Skin Promotes in Vitro Angiogenesis through Endothelial to Mesenchymal Transition during Skin Wound Healing. Int. J. Mol. Sci. 2017, 18, 1614. https://doi.org/10.3390/ijms18081614

AMA Style

Belvedere R, Bizzarro V, Parente L, Petrella F, Petrella A. The Pharmaceutical Device Prisma® Skin Promotes in Vitro Angiogenesis through Endothelial to Mesenchymal Transition during Skin Wound Healing. International Journal of Molecular Sciences. 2017; 18(8):1614. https://doi.org/10.3390/ijms18081614

Chicago/Turabian Style

Belvedere, Raffaella; Bizzarro, Valentina; Parente, Luca; Petrella, Francesco; Petrella, Antonello. 2017. "The Pharmaceutical Device Prisma® Skin Promotes in Vitro Angiogenesis through Endothelial to Mesenchymal Transition during Skin Wound Healing" Int. J. Mol. Sci. 18, no. 8: 1614. https://doi.org/10.3390/ijms18081614

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop